NCT03948529 2025-09-30
REGALIA
University Hospital, Lille
Phase 2 Terminated
Clinical Trials
13 trialsNCT06630221 2025-07-03
Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03603795 2024-10-29
EPAG2015
French Innovative Leukemia Organisation
Phase 2 Active not recruiting
NCT02446145 2024-03-29
DELTA
Technische Universität Dresden
Phase 2 Terminated
NCT01168921 2023-03-23
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02071901 2021-12-01
Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy
Case Comprehensive Cancer Center
Phase 2 Unknown
NCT01893372 2020-02-18
Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02010645 2020-01-02
Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01890746 2019-09-11
A Safety and Efficacy Study of Eltrombopag in Subjects With AML
Novartis
Phase 2 Completed
NCT01610180 2018-07-16
Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)
Fondazione Progetto Ematologia
Phase 2 Completed
NCT01440374 2017-06-05
ASPIRE
Novartis
Phase 2 Completed
NCT01488565 2016-02-15
Aza-E
Peter MacCallum Cancer Centre, Australia
Phase 2 Completed
NCT01757145 2015-06-19
Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation
Rabin Medical Center
Phase 2 Unknown